Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quizartinib - Daiichi Sankyo Company

Next Previous
Drug Profile

Quizartinib - Daiichi Sankyo Company

Alternative Names: AC-010220; AC-220; ASP-2689; VANFLYTA

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony-stimulating factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Solid tumours

Most Recent Events

  • 16 Jun 2025 Registered for Acute myeloid leukaemia (Combination therapy, First-line therapy) in Canada (PO)
  • 12 Jun 2025 Daiichi Sankyo completes a phase I trial (In volunteers) in USA (PO) (NCT06772246)
  • 13 Feb 2025 Daiichi Sankyo plans to initiate a phase II trial for Acute Myeloid Leukemia (PO) (NCT06824168)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top